Lipocine Inc. (NASDAQ: LPCN) will present and meet investors at the H.C. Wainwright conference on September 16, 2026. Investors can access the presentation through a live webcast and later replay in the Events section of Lipocine’s website, giving them scheduled online access to management’s conference presentation.

Key Highlights

  • The conference will take place in person and virtually from September 14 to September 16, 2026.
  • Lipocine’s webcast and replay will be available through the Events section of its website.
  • The development pipeline includes LPCN 1154, LPCN 2201, LPCN 2101, LPCN 2203, LPCN 2401, LPCN 1148 and LPCN 1107.

Lipocine (NASDAQ: LPCN) Sets September 16 Conference

Presentation Management will present during the conference, which runs from September 14 through September 16, 2026. Lipocine (NASDAQ: LPCN) said investors seeking one-on-one meetings should contact an H.C. Wainwright representative. Lipocine describes itself as a biopharmaceutical company developing oral therapeutics through its proprietary technology platform. Its pipeline includes LPCN 1154 for postpartum depression, LPCN 2201 for major depressive disorder, LPCN 2101 for epilepsy and LPCN 2203 for essential tremor.

Webcast Access Extends Beyond The Live Event

The webcast will be archived for a stated period following the live event. Investors can also arrange individual meetings through the conference representative. Lipocine said TLANDO, its oral testosterone undecanoate prodrug, is approved by the FDA for conditions linked to endogenous testosterone deficiency in adult males.